Entropy Neurodynamics (ASX:ENP)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Entropy Neurodynamics.
RELATED STOCKHEAD STORIES
Second patient joins world-first Tryptamine psilocin trial targeting binge eating disorder
Health Check: Our flu recovery prognosis is positive, CSL tells investors
Break it Down: Tryptamine raises $6.1m to fast-track world-first binge eating disorder trial
Health Check: Despite selling life-saving tech, Uscom faces its honourable demise
StockTake: First patient joins Tryptamine’s world-first IV psilocin trial for binge-eating disorder
Tryptamine secures landmark EEG biomarker deal to advance precision psychiatry
Health Check: Biotechs rush to short-term funding fix
Tryptamine gains regulatory approvals for world-first IV psilocin binge eating trial
MoneyTalks: Summit Biotech Fund’s three standout ASX healthcare stocks
Disorder to go: Tackling the deadliest psychological illnesses no one is talking about
Biocurious: It’s a case of animal magnetism as Island eyes the FDA’s new rule on non-human testing
Tryptamine opens patient recruitment for world-first Binge Eating Disorder trial
Health Check: On Lamington Day, biotechs serve up their chocolate-dipped quarterly morsels
